Study to Evaluate the Safety and Immunogenicity of 'IL-YANG Flu Vaccine Quadrivalent Inj' in Healthy Korean Adults

Influenza, Human Clinical Trial

Official title:

A Randomized, Double-blind, Active Comparator, Phase I/Ⅱa Clinical Trial to Assess the Safety and Immunogenicity of the 'IL-YANG Flu Vaccine Quadrivalent Inj.' in Healthy Korean Adult Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02480998
• Other study ID #: IY_IFEZ_Q120
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: February 2015
• Est. completion date: April 2015

Study information

• Verified date: July 2020
• Source: Il-Yang Pharm. Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study evaluates the safety, tolerability and immunogenicity of IL-YANG quadrivalent vaccine versus IL-YANG trivalent vaccine after a single intramuscular administration in healthy Korean males and females 19 to < 65 years of age.

Description:

This is a randomized, double-blind, active-controlled, phase I/Ⅱa clinical trial.

During the Part A phase, all safety data collected from the 12 subjects enrolled in the Part A phase will be analyzed to determine the safety and tolerability of the investigational product, which should include any solicited and unsolicited adverse drug reactions occurring for the first 7 days after vaccination and any adverse events occurring for 28 days after vaccination. Antibody titer test will be also performed to evaluate the efficacy (immunogenicity) of the investigational product. During the Part B phase, a total of 72 subjects will be enrolled, and all safety data (including all adverse events) and immunogenicity data will be analyzed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 84
• Est. completion date: April 2015
• Est. primary completion date: April 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 19 Years to 64 Years

Eligibility

Inclusion Criteria:

• Healthy men and women 19 to < 65 years of age at screening

• Body weight within ±20% of ideal body weight at screening

• Women of childbearing potential must have a negative serum beta-hCG at visit 2; and agree to use a proper contraceptive method for 1 month after vaccination (starting from 3 months before screening), using a medication or device that does not have any drug-interaction with the investigational product.

• Subjects with no congenital or chronic disease who were considered suitable for the study after screening assessments (investigator's opinion, medical history, physical examination, laboratory test, chest X-ray, and ECG) conducted no later than 28 days prior to vaccination

• Subjects who were given, and fully understood, the information about the study, and have provided voluntary written informed consent to participate in the study and to comply with all applicable study requirements

Exclusion Criteria:

• Subject with known allergy to eggs, chicken, or any components of the investigational product

• Subjects who had received an influenza vaccine within the last 6 months prior to study entry

• Subjects who have known or suspected infection with HAV, HBV, HCV, HIV or VDRL

• Subjects who have concurrent or a past history of, immune deficiency disease

• Subject with a history of Guillain-Barre syndrome

• Subject with hemophilia or thrombocytopenia or being treated with an anticoagulant, who are at increased risk of serious bleeding during intramuscular injection

• Subjects with known allergy to a drug, food or latex, who had a history of anaphylaxis

• Subjects who had an acute fever with body temperature > 38.0 Cº within 72 hours prior to administration of the investigational product or symptoms of suspected acute disease within 14 days prior to administration of the investigational product

• Subjects who had received another vaccine within 28 days before administration of the investigational product or are planning to receive another vaccine during the study.

• Subjects who had participated in another clinical trial within the 30 days before administration of the investigational product.

• Subjects who had previously received blood-derived products (including immunoglobulin) within the last 3 months prior to administration of the Investigational product, or are scheduled to receive a treatment with blood-derived products during the study

• Subjects who had received, or are scheduled to receive, systemic immunosuppressive therapy, radiation therapy or high-dose steroid therapy within the last 6 months prior to administration of the study

• Subjects with a history of drug abuse within the last 6 months prior to vaccination, or is suspected of drug abuse

• Subjects with excessive consumption of caffeine, alcohol, or tobacco

• Subjects with other clinically significant medical or psychiatric illness who in the investigator's opinion, are not be suitable for the study

Related Conditions & MeSH terms

• Influenza, Human

Intervention

Biological:
• IL-YANG Flu Vaccine QIV 0.5mL

• IL-YANG Flu Vaccine TIV 0.5mL

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Il-Yang Pharm. Co., Ltd.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Seroconversion Rate	Percentage of subjects achieving seroconversion* for HI antibody after vaccination	28 days
Primary	Seroprotection Rate	Percentage of subjects achieving seroprotection* for HI antibody after vaccination	28 days
Secondary	GMR	Geometric Mean Ratio of post vaccination HI geometric mean titers	28 days
Secondary	GMT	Geometric Mean Titer of post vaccination HI geometric mean titers	28 days